Japan's Cyfuse has just closed $12M Series B funding round to help it develop a bioprinter capable of building human tissue.
Cyfuse Biomedical has announced that it has completed a 1.4 billion yen ($12M) Series B funding round participated in by 12 investors, including venture capital funds and corporate investors.
This brings the total investment in Cyfuse to 1.98 billion yen ($16.5M), including capital reserve. With this funding, Cyfuse will begin overseas sales of its bio 3D printer for research applications and also accelerate the development of its 3D tissue engineering technology for regenerative medicine applications.
Company overview
Cyfuse is a regenerative medicine startup founded in 2010 to develop its proprietary technology to assemble living cells in three dimensions. The technology is based on the research results of Professor Koichi Nakayama of Saga University during his time at the Department of Orthopedic Surgery at Kyushu University.
– Technology overview
The company’s technology uses a fine needle array to skewer cellular aggregates (0.5mm diameter), which are then stacked three dimensionally.
Future business development
With this round of funding, Cyfuse plans to increase its headcount and launch the overseas sales of the Regenova bio 3D printer and expand research seeds though collaboration with the academic community. In addition, Cyfuse will establish a cell processing facility for clinical use and apply its platform technology and expand its use by putting in place a system to subcontract manufacturing of the tissue from university hospitals and other institutions.